Philips CPAP Recall Lawsuit MDL 3014 — 2026 Plaintiff Guide

The Philips CPAP recall is one of the largest medical device safety crises in recent US history. Millions of devices were recalled in June 2021. Two separate multi-billion-dollar settlements have followed. And yet — as of May 2026 — the litigation is not over.

Understanding why requires separating the three parallel tracks in MDL 3014 and knowing which one applies to your situation. This guide is written for US plaintiffs evaluating whether to pursue a claim, what to document, and how to find a qualified MDL attorney. Nothing here constitutes legal advice; your specific situation requires consultation with a licensed attorney.

---

The Core Problem: What the PE-PUR Foam Actually Does

Philips Respironics built polyester-based polyurethane (PE-PUR) foam into its CPAP, BiPAP, and ventilator devices primarily to reduce operating noise. The foam was positioned inside the airway pathway — the same channel through which patients breathe during sleep.

The design flaw emerged gradually. Under conditions of heat, humidity, or ozone cleaning, PE-PUR foam degrades in two ways that create direct health exposure:

Particulate release. As foam breaks down, microscopic polymer particles detach and enter the breathing circuit. Patients inhale these particles directly into lung tissue over months or years of nightly use.

Chemical off-gassing. Foam degradation produces volatile organic compounds and chemical gases, including isocyanates — a class of compounds linked to respiratory sensitization and, in certain forms, classified as possible carcinogens by the International Agency for Research on Cancer (IARC).

Philips’ June 2021 recall notice specifically warned that the degradation risk was amplified by storage in high-heat, high-humidity conditions and — critically — by the use of ozone-based cleaning devices that Philips had not authorized. Many users were routinely cleaning their machines with third-party ozone units, inadvertently accelerating the foam’s breakdown.

---

The Class I Recall: Scope and Scale

On June 14, 2021, Philips issued a voluntary recall notification to the FDA. The FDA classified it as a Class I recall — the most serious designation, reserved for products where “use of, or exposure to, a violative product may cause serious adverse health consequences or death.”

Recalled devices span roughly the 2008–2021 production window. The primary product lines affected include:

Product Category	Example Models	Notes
CPAP	DreamStation, SystemOne, REMstar	Core recall group
BiPAP / BiLevel	DreamStation BiPAP, BiPAP Pro, autoSV	Included
Mechanical Ventilators	Trilogy Evo, Garbin Plus	Subset of models
ASV Devices	DreamStation ASV, BiPAP autoSV Advanced	Included

The DreamStation 2, which entered the market in 2021, used a different foam material and is not part of the recall. Verify your device’s inclusion by entering the serial number at Philips’ official recall lookup portal.

---

MDL 3014: Three Separate Tracks, Three Different Outcomes

Judge Joy Flowers Conti in the Western District of Pennsylvania consolidated thousands of Philips claims into MDL 3014. As of May 2026, approximately 622 cases remain active before her. Understanding the three-track structure is essential before evaluating your position.

Track 1 — Economic Loss Class Action (Resolved: September 2023)

Philips agreed to a $479 million settlement in September 2023 to resolve economic loss claims. This covers the financial cost of the device itself, not physical injury.

Who this applies to: Anyone who purchased, rented, or leased a covered device and either didn’t experience physical injury or chose to participate in this class rather than the injury track.

Payment range: $50 to $1,500 per claimant, depending on device type and how it was acquired. An additional $34 million was set aside for health insurers and reimbursement entities. Distributions began in early 2024.

Critical note: Accepting an economic loss payment does not automatically waive personal injury claims — but review your release documents carefully with an attorney.

Track 2 — Personal Injury Settlement (Announced: April 2024)

In April 2024, Philips announced an approximately $1.1 billion settlement framework to resolve personal injury claims.

Who this applies to: Individuals diagnosed with cancer, significant lung damage, or serious respiratory disease following use of a recalled device.

The specific allocation matrix — how individual claims are valued relative to diagnosis, severity, and other factors — was not publicly disclosed. Cases that opt out of the settlement, or claims that remain unresolved, will continue toward trial.

Track 3 — Medical Monitoring Class Action (Preliminary Approval: June 2024)

A $25 million medical monitoring class action received preliminary approval in June 2024, with a fairness hearing scheduled for October 30, 2024.

Who this applies to: Recalled device users who have not yet developed a diagnosed condition but want ongoing health surveillance to catch any future development.

This is a prophylactic track. Participation does not preclude personal injury claims if a condition later develops.

---

Diseases Alleged in MDL 3014 Claims

Plaintiffs in MDL 3014 have alleged a range of conditions connected to PE-PUR foam exposure:

Respiratory and pulmonary

• Lung cancer
• Non-cancerous pulmonary injury
• Hypersensitivity pneumonitis
• Airway inflammation and chronic cough

Systemic

• Kidney cancer
• Liver cancer
• Headaches, dizziness, nausea (acute chemical exposure)
• Inflammatory conditions

The causation science remains actively contested in the MDL. Defense experts argue that available exposure data does not establish sufficient carcinogenic dose levels. Plaintiff experts counter with bioaccumulation studies and occupational health data on isocyanate exposures. Bellwether trial outcomes will be the first real test of how juries weigh these arguments.

---

Three Plaintiff Scenarios: Evaluating Your Position

These are fictional scenarios, not legal advice. They illustrate how eligibility questions typically surface.

Scenario 1: Long-Term User, Recent Cancer Diagnosis

A 58-year-old in Ohio used a recalled DreamStation from 2015 to 2021, cleaning it weekly with an ozone cleaner. He was diagnosed with lung cancer in 2024, with no significant smoking history.

This person has a plausible personal injury claim profile: covered device, extended ozone-accelerated exposure, subsequent cancer diagnosis, limited confounding factors. Statute of limitations likely runs from the 2024 diagnosis date under Ohio’s discovery rule. MDL personal injury track is directly relevant.

Scenario 2: Device Owner, No Health Issue

A 44-year-old in Florida purchased a recalled SystemOne in 2018 and received a replacement device through Philips in 2022. No health issues have emerged.

Track 1 economic loss settlement applies. The replacement program may also have generated a credit. Medical monitoring participation (Track 3) provides long-term surveillance. If a health issue emerges in future years, the discovery rule may restart the personal injury clock at that point.

Scenario 3: Deceased Loved One Who Used a Covered Device

A family in Pennsylvania lost a parent to lung cancer in 2023. The parent had used a recalled CPAP for over a decade. No claim was filed before death.

Wrongful death or survival action may be available, typically filed by the estate or surviving family members. Timeline is time-sensitive because some states require filing within a shorter window after the decedent’s death. Immediate consultation with an MDL attorney is advisable.

---

Document Checklist: What to Gather Now

Document Type	Details	Priority
Device serial number	From device label or Philips account	Critical
Purchase / lease records	Receipt, DME supplier contract	Critical
Medical records	Diagnosis documents, imaging, pathology	Critical
CPAP prescription	Prescribing physician, date, device specs	High
Insurance billing	Claims submitted for device/repairs	Supporting
Cleaning device records	Ozone cleaner purchase/use if applicable	Supporting
Employment records	If seeking lost income damages	If applicable

Preserve any physical foam debris you notice in the device’s air tubing. If you’ve already returned or replaced the device, the return confirmation and replacement paperwork serve as substitute evidence.

---

Finding the Right MDL Attorney

General personal injury attorneys often lack the procedural knowledge and plaintiff infrastructure required in complex MDL cases. Look specifically for:

• MDL 3014 case portfolio — Ask if the firm has active cases in this specific MDL
• Plaintiffs’ leadership role — Firms on the Plaintiffs’ Steering Committee have greatest visibility into case developments
• Contingency-only fee structure — No upfront cost; typically 33–40% upon recovery
• No outcome guarantees — Any attorney promising a specific settlement amount should be avoided
• Free initial consultation — Standard in mass tort practice

For a broader understanding of how contingency fee arrangements work in mass tort cases, see our guide to personal injury attorney fees in 2026. For context on how MDL settlement timelines generally unfold, see mass tort settlement payout timelines.

---

The Ozone Cleaner Problem: Accelerated Exposure and Contributory Fault

One aspect of the Philips recall that generates significant legal complexity is the role of third-party ozone-based cleaning devices. Philips’ recall notice specifically identified ozone cleaning as a factor that accelerates PE-PUR foam degradation — and yet, millions of users had been routinely using ozone cleaners like SoClean and Lumin to sanitize their CPAP equipment.

These products were aggressively marketed to CPAP users as superior hygiene solutions, often sold through the same medical equipment suppliers and with the same authoritative-sounding safety messaging. Many users genuinely believed they were taking better care of their equipment by using ozone cleaning.

The legal tension: On one hand, a plaintiff who used ozone cleaning may have faced greater foam degradation and thus greater toxic exposure — which supports a stronger personal injury claim. On the other hand, Philips will argue that users who employed unauthorized cleaning methods bear some contributory fault for modifying the device’s operating environment.

How courts and juries ultimately apportion fault between Philips (for the defective foam design) and any plaintiff (for unauthorized cleaning use) will depend on each state’s comparative fault rules. In states that follow pure comparative fault principles, a plaintiff can still recover even if partially at fault. In contributory fault states, findings of plaintiff fault can eliminate or reduce recovery substantially.

Document your ozone cleaner use — model, frequency, duration — because it will be a factual issue in claim evaluation.

---

Why the Personal Injury Settlement Amount Is Hedged

The “approximately $1.1 billion” figure attached to the April 2024 personal injury settlement announcement requires careful interpretation. This figure represents the reported size of the settlement pool — the total amount Philips agreed to make available to resolve personal injury claims — not what any individual plaintiff will receive.

Mass tort settlement pools are distributed through a points-based or matrix-based allocation system, typically developed by a Special Master appointed by the court and the Plaintiffs’ Steering Committee. Factors that typically drive individual allocation include:

• Diagnosis severity — Cancer diagnoses generally rank higher than non-cancerous respiratory injury
• Duration of device use — Longer and more recent use correlates with greater presumed exposure
• Treatment costs — Documented medical expenses
• Lost income — If the injury caused work incapacity
• Age at diagnosis — Younger plaintiffs with longer expected future harm periods often receive more
• Pre-existing conditions — Smoking history, prior lung disease, other cancers reduce individual allocations

Claims that do not resolve through the settlement pool — either because plaintiffs opt out or because Philips contests a specific claim — proceed toward individual trial in the MDL’s home jurisdiction.

---

The Causation Debate: What Defense Experts Will Argue

Defense attorneys in MDL 3014 face a difficult factual environment — a Class I recall, internal company documents, and prior admissions that the foam degrades and releases harmful particles create a strong plaintiff foundation. But causation for individual cancer claims remains genuinely contested.

Defense experts are expected to argue:

Dose response uncertainty. Regulatory toxicology typically requires evidence that an exposure dose was sufficient to cause the specific disease. How much PE-PUR foam degradation occurred in any individual device, over what time period, and whether the resulting exposure reached a biologically significant threshold is highly device-specific.

Alternative carcinogen exposure. Cancer is multifactorial. Defense experts will emphasize tobacco use, occupational exposures, family history, and other risk factors as alternative or contributing causes.

Background rate analysis. Lung cancer and kidney cancer occur in the general population at significant baseline rates. Defense experts will contest whether CPAP users have statistically elevated rates compared to matched controls with equivalent demographic and health profiles.

Plaintiff experts counter these arguments with bioaccumulation studies, occupational health data on isocyanate carcinogenicity, and the argument that even low-dose chronic exposure to known carcinogens is actionable under established products liability principles.

These competing narratives will play out before juries in bellwether trials — which is why the selection and outcome of those test cases matter so much to the final settlement value of the entire MDL.

---

How MDL 3014 Compares to Other Active Medical Device Litigations

The Philips CPAP MDL follows structural patterns established by earlier large-scale medical device litigations:

Parallel economic/injury tracks — Similar to how transvaginal mesh litigation separated device removal costs from personal injury claims.

Bellwether trials as settlement pressure — Test cases are selected to go to trial, with verdicts informing the settlement value of the broader pool. MDL 3014 has bellwether trials scheduled in the 2024–2026 window.

Medical monitoring as a separate class — A mechanism increasingly used in large product liability MDLs where a large population was exposed but not all have yet developed disease.

For related medical device litigation developments, see our coverage of Bard PowerPort catheter lawsuits and hernia mesh lawsuits.

---

What Happens to Unresolved Claims After Settlement

Plaintiffs who opt out of settlement negotiations, or whose claims are not captured by existing settlement structures, have the right to pursue individual trials. In practice, this path is taken by claimants with unusually high-value claims — severe cancer diagnoses, significant documented exposure, or deaths — where the settlement allocation matrix may undervalue their losses.

Post-settlement structured payment arrangements are common in mass tort resolutions. If you receive a lump sum from an MDL settlement, you may also have options for managing that payment — see structured settlement cash-out options for context.

---

What Happens to Wrongful Death Claims

For families who lost a loved one after that person used a recalled Philips device and was later diagnosed with a related cancer, wrongful death and survival actions are available. These claims are brought by the estate of the deceased, and in many states by surviving spouses, children, or parents, depending on state law.

Key differences from standard personal injury claims:

Survival actions permit the estate to recover damages the deceased would have been entitled to recover — medical expenses, pain and suffering — from the time of injury until death.

Wrongful death actions permit certain surviving family members to recover for their own losses — loss of companionship, financial support, household services — resulting from the wrongful death.

Both types of claims are subject to state-specific statutes that determine who can file, what damages are available, and the applicable time limits. The interplay between survival and wrongful death statutes, and state-specific caps on non-economic damages, makes these cases among the most legally complex in MDL 3014. Families in this situation should prioritize consulting an MDL attorney promptly, as wrongful death limitation periods often run from the date of death and can be shorter than standard personal injury limitation periods.

---

The Special Issue of Medicare and Medicaid Liens

CPAP users who are covered by Medicare or Medicaid face an additional financial consideration that many plaintiffs are unaware of: Medicare and Medicaid liens on settlement proceeds.

Under the Medicare Secondary Payer Act (MSP, 42 U.S.C. § 1395y(b)), Medicare is a secondary payer when a primary plan — including a tort recovery — is available. If Medicare paid for medical care related to the recalled device injury (respiratory treatment, cancer treatment), it has a statutory right to be reimbursed from any settlement or judgment.

The practical implication: a plaintiff who receives a $300,000 personal injury settlement may discover that Medicare has a lien for $80,000 in related medical expenses that must be repaid before the plaintiff can access the balance. Medicaid liens work similarly under federal law, though the specific rules differ by state.

MDL-experienced attorneys understand how to negotiate Medicare and Medicaid lien amounts as part of the settlement process — a skill that general personal injury attorneys often lack. The lien amount can sometimes be significantly reduced through negotiation, particularly in cases where the settlement is for less than full value of the claim.

Confirm with your MDL attorney before finalizing any settlement whether Medicare or Medicaid lien obligations have been properly identified and negotiated.

---

Understanding the Bellwether Trial Process and What It Means for You

The bellwether trial concept is central to MDL case management but is often misunderstood by plaintiffs. Understanding it helps set realistic expectations.

In a typical MDL with thousands of cases, it is logistically and economically impossible to try every case individually before reaching settlement. Instead, the parties — usually through a committee of Plaintiffs’ Steering Committee and defense counsel, supervised by the court — select a small number of representative cases (bellwethers) to go through the full trial process.

How cases are selected: Bellwether cases are chosen to be representative of the broader MDL pool — by injury type, device model, exposure duration, plaintiff demographics. Neither extreme outliers (the weakest or strongest cases) nor unusual edge cases are selected, because the goal is to generate verdicts that are informative about the typical case value.

What bellwether verdicts do: The outcomes tell both sides — with concrete, jury-tested data — what a typical case is worth. A high plaintiff verdict in three consecutive bellwether trials signals to defendants that settling the remaining pool at substantial per-case values is preferable to continuing trial risk. A series of defense verdicts signals the opposite.

What they don’t do: A bellwether verdict does not bind other plaintiffs. Your case is not decided by the bellwether trial. However, the settlement framework that follows is heavily influenced by it, and attorneys use bellwether outcomes to negotiate individual case values.

For context on how MDL settlement payments are structured and disbursed after verdicts establish reference values, see mass tort settlement payout timelines 2026.

---

State-Specific Statute of Limitations: The Most Urgent Issue

If there is one action that MDL 3014 plaintiffs most frequently delay to their legal detriment, it is confirming the applicable statute of limitations for their state of residence at the time of injury.

While the discovery rule generally extends the limitation period to when the plaintiff knew or reasonably should have known that their illness was connected to the device, the baseline limitation period and the discovery rule’s application vary significantly by state:

State	Standard Products Liability Limitation	Notes
California	2 years from discovery	Discovery rule broadly applied
Florida	4 years	Broader discovery rule
New York	3 years	Strict discovery rule application
Texas	2 years from discovery	Relatively strict in cancer context
Pennsylvania (MDL home state)	2 years from discovery	Federal MDL does not extend state SOL
Ohio	2 years	Various tolling provisions

The practical urgency: if you were diagnosed with a cancer that may be related to CPAP use, consult with an MDL attorney before that 2-year window from your diagnosis date closes, regardless of which track you ultimately pursue. The MDL filing does not toll (suspend) your state’s limitation period unless specific conditions are met.

---

Protecting Your Health Rights Separate From Litigation

The litigation process and your medical rights are parallel, not identical. Actions that protect your health also strengthen your legal claim — making this a situation where following the advice of treating physicians and a litigation attorney are aligned:

Get pulmonary function testing. If you used a recalled device for more than a year, baseline pulmonary function tests and imaging create a benchmark. Any future decline is documented. Any current pathology is identified.

Report symptoms to your physician immediately. Chronic cough, unexplained weight loss, blood in sputum, progressive breathlessness — any of these symptoms in a former recalled device user should be evaluated urgently, not attributed to “CPAP side effects” without proper workup.

Request referral to a pulmonologist or oncologist. Your primary care physician can facilitate specialist evaluation. Documented specialist consultation creates a medical record trail that is valuable both for your health and for any future litigation.

Join the medical monitoring class. If eligible, enrollment in the $25 million medical monitoring settlement class provides structured access to surveillance testing that your physicians may not know to order otherwise.

---

The Position This Case Is In Right Now

MDL 3014 is not resolved. The economic loss track has distributed payments. The personal injury settlement framework has been announced but individual claim processing remains ongoing. Bellwether trial schedules for unresolved claims are pending.

For plaintiffs: the window to document, file, and participate in these tracks has not permanently closed — but it is narrowing. Any person who used a recalled device and subsequently developed a serious respiratory or cancer diagnosis should consult with an MDL-experienced attorney now rather than waiting for additional public announcements.

---

Frequently Asked Questions for Specific Situations

I returned my CPAP years ago. Is it too late?

Not necessarily. The return itself may be documented evidence that you used a covered device. Prescription records, sleep clinic records, and insurance billing history can substitute for physical possession of the device. The limitation period analysis turns on when your illness was diagnosed and when you connected it to the device — not when you used or returned it.

My recalled CPAP was a rental, not a purchase. Does that change my claim?

No. The economic loss settlement covered renters and leasers as well as purchasers. For personal injury claims, the device use history matters, not the purchase structure. Rental records through your DME (durable medical equipment) supplier establish the use history.

I used the CPAP for only six months before returning it. Is my exposure too limited to support a claim?

This is a medical-legal question that depends on your specific diagnosis and the expert evidence available. Short exposure periods can still support claims, particularly for conditions with steep dose-response curves or for individuals with particular vulnerability factors. An experienced MDL attorney can assess whether the exposure duration in your specific case is likely to be defensible.

I received the economic loss settlement payment of $175. Does that preclude a personal injury claim?

Potentially not — but you must review the release you signed as part of the economic loss settlement. Some releases are broad enough to affect personal injury claims; others are specifically limited to economic loss. Do not assume either way without showing the documents to an attorney.

My cancer is not lung cancer — it’s kidney cancer. Can I still file?

Yes. MDL 3014 personal injury claims have been filed for multiple cancer types alleged to be associated with isocyanate and other chemical exposure, including kidney cancer and bladder cancer. The specific causal pathway expert analysis differs by cancer type, but the claims are viable.

For additional guidance on mass tort litigation structure and timelines, see class action settlement structures 2026 and data breach class action settlements 2026.

My doctor says the CPAP was fine and the cancer is unrelated. Should I still consult an MDL attorney?

Yes. Your treating physician’s view on causation is one data point — not the final word. MDL 3014 plaintiffs’ firms retain independent medical and toxicological experts who evaluate the specific exposure-cancer connection for each patient. If you used a covered device for a meaningful period and developed a cancer type consistent with the alleged chemical exposures, an independent expert evaluation is worthwhile regardless of your treating doctor’s initial opinion.

---

Disclaimer: This article is for informational purposes only and does not constitute legal advice. MDL 3014 eligibility, statute of limitations, and potential recovery depend on individual facts that must be evaluated by a licensed attorney experienced in mass tort litigation. No specific outcome or compensation amount is promised or implied.